MAGAZINE

PLOS ONE

Retinal changes in COVID-19 hospitalized cases

AUTHORS & DATE

Rafael Lani-LouzadaI, Carolina do Val Ferreira Ramos, Ricardo Mello Cordeiro, Alfredo A. Sadun
03/12/2020

Abstract

Background

The main objective of this study was to evaluate the retinas of severely or critically ill COVID-19 patients during their hospital stay, at varying time points after symptoms onset.

Methods

This was a case series observed during May 2020 in two referral centers for COVID-19 treatment in Rio de Janeiro, Brazil. 47 eyes from 25 hospitalized patients with severe or critical confirmed illness were evaluated. A handheld retinal camera was used to acquire bilateral fundus images at several time points after symptoms onset. Electronic health records were retrospectively analyzed and clinical data collected.

Results

Severe and critical diseases were noticed in 52% (13/25) and 48% (12/25) of enrolled patients, respectively. Retinal changes were present in 12% (3/25) of patients: a 35 year-old male demonstrated bilateral nerve fiber layer infarcts and microhemorrhages in the papillomacular bundle, but required mechanical ventilation and developed severe anemia and systemic hypotension, acute kidney injury and neurologic symptoms during the course of the disease (critical illness); a 56 year-old male, who required full enoxaparin anticoagulation due to particularly elevated D-dimer (>5.0 mcg/mL), demonstrated unilateral and isolated flame-shaped hemorrhages; and a 49 year-old hypertensive male showed bilateral and discrete retinal dot and blot microhemorrhages. The other 22 patients evaluated did not demonstrate convincing retinal changes upon examination. There was no correlation between disease severity and admission serum levels of CRP, D-dimer and ferritin. This was the first study to show that vascular retinal changes may be present in not insignificant numbers of severe or critical COVID-19 inpatients.

Conclusion

These retinal changes, only seen after morbid developments, were likely secondary to clinical intercurrences or comorbidities instead of a direct damage by SARS-CoV-2, and may be important and easily accessible outcome measures of therapeutic interventions and sentinels of neurologic and systemic diseases during COVID-19 pandemic.

Icon Button Request A QuoteRequest a Quote

Fechar

Ico Back

Later

Request a quote

Fill out the form below and we will contact you shortly.

    Ico Form Success

    Request a Quote

    Our team will contact you shortly.

    Close

    …complete suas informações

      By clicking the Complete button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
      Ico Back

      Depois

      Ico Form Success

      Obrigado por completar suas informações

      FECHAR

      Ico Back

      Depois

      Solicite e comece SEU TEST DRIVE

      Por favor, preencha o formulário abaixo que entraremos em contato.

        x

        Solicitar Orçamento

        Ao clicar em Solicitar, concordo com a Política de Privacidade e os Termos de Uso, permito que a Phelcom me contate e reconheço que o Eyer é um dispositivo médico (Anvisa classe II) exigindo a supervisão de um profissional com CRM para uso e interpretação das imagens.
        Ico Form Success

        Obrigado!

        Nosso time comercial logo entrará em contato para finalizar o processo.

        FECHAR

        Ico Back

        Later

        Request more information

        Please fill out the form below and we will contact you.

          x

          Request EyerMaps

          By clicking the Request button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
          Ico Form Success

          Thank you!

          Our commercial team will contact you shortly to finalize the process.Our commercial team will contact you shortly to finalize the process.
          CLOSE